Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 4Phase 3 3Phase 2/3 2Phase 1 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 8Nivolumab 8Biopsy 7Radiotherapy 6Temozolomide 4Specimen Handling 4Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Surgical Procedures, Operative 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3Aspirin 3perflutren 2alovudine 2Tirzepatide 2Rituximab 2Positron-Emission Tomography 2Phantoms, Imaging 2Omeprazole 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Immunotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × relatlimab × 90 days × Clear all
NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡